Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
about
Postprandial C-Peptide to Glucose Ratio as a Marker of β Cell Function: Implication for the Management of Type 2 DiabetesWhat's next after metformin? focus on sulphonylurea: add-on or combination therapyAssessment of pancreatic β-cell function: review of methods and clinical applicationsInterventions to preserve beta-cell function in the management and prevention of type 2 diabetesA low-carbohydrate high-fat diet increases weight gain and does not improve glucose tolerance, insulin secretion or β-cell mass in NZO mice.β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.Practical combination therapy based on pathophysiology of type 2 diabetesRestoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life spanPathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.A cross-sectional view of the current state of treatment of youth with type 2 diabetes in the USA: enrollment data from the Pediatric Diabetes Consortium Type 2 Diabetes Registry.Correlation of Circulating Acid-Labile Subunit Levels with Insulin Sensitivity and Serum LDL Cholesterol in Patients with Type 2 Diabetes: Findings from a Prospective Study with RosiglitazoneInadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes MellitusFactors associated with beta-cell dysfunction in type 2 diabetes: the BETADECLINE study.Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial.Intensive therapy in newly diagnosed type 2 diabetes: results of a 6-year randomized trialDurability of oral hypoglycemic agents in drug naïve patients with type 2 diabetes: report from the Swedish National Diabetes Register (NDR).Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial.Importance of Beta Cell Function for the Treatment of Type 2 DiabetesComparative effectiveness of incident oral antidiabetic drugs on kidney functionSignificant retinopathy in young-onset type 2 vs. type 1 diabetes: a clinical observation.The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitusSitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trialImpact of differences in glucose tolerance on the prevalence of a negative insulinogenic index.Interactions between genetic background, insulin resistance and β-cell function.Efficacy and safety of avandamet or uptitrated metformin treatment in patients with type 2 diabetes inadequately controlled with metformin alone: a multicenter, randomized, controlled trialProgressive deterioration of β-cell function in obese youth with type 2 diabetesEffects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY.Monomethylated-adenines potentiate glucose-induced insulin production and secretion via inhibition of phosphodiesterase activity in rat pancreatic islets.Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.Using oral challenge testing to assess insulin action and secretion with mathematical modeling.Relationships of the early insulin secretory response and oral disposition index with gastric emptying in subjects with normal glucose tolerance.Managing diabetes from first diagnosis: choosing well-tolerated therapies with durability.Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes.Zinc as a potential coadjuvant in therapy for type 2 diabetes.The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes.Current management of diabetes mellitus and future directions in care.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes.
P2860
Q26747696-4FC27D1A-CC64-42F8-82DB-ACD436BCAD92Q26786524-DC17BAFA-9276-433E-A769-0D0CC5B5622BQ26829445-E1A7C192-2CB1-4881-92DB-91274037E9F0Q26830871-ED0B3BB8-3AFC-472C-B874-3CD084A24C08Q27310129-F43DD55E-396A-40C0-9794-7B4EFF1CE310Q27692665-790745C0-695D-44CF-8667-B924806FEA8AQ28076530-21CEB52F-6914-4D83-B5D6-0146BE64B9B7Q30572405-C78FDB86-452D-4F05-8AD6-A27356BB79EDQ30597265-609C3670-CC8D-41B2-8EC0-76B37BE2DFEEQ31057431-7107D5BD-FC29-40C5-987D-3CB324F3AA71Q33748524-DC66129B-5CD9-471D-AEC3-9ABBA841EA85Q33775600-22E39FEF-D45E-4FF1-9372-9B82A4046E24Q34407830-06932823-2D9C-4920-B29C-0B8D9BF41464Q34516303-96999F60-7067-48BB-B1B7-0F5F12D68F53Q34586302-D6731180-06D0-40ED-B3B8-5B6635C97DCFQ35203980-414C39F5-E013-481D-9739-AD6A97B1BD6FQ35225372-83F41838-A407-4B0D-90A9-5767094A09F5Q35667116-E2A86CDC-E303-4B78-B13B-52FE62B21A16Q35835288-5FFB1F2D-CE12-4082-BDAE-C8B6E1255B6FQ35974230-9CADB07D-A5CE-4293-8EED-906567186FCAQ36592820-7FD36464-77CD-4518-980F-AC0875037F1EQ36625527-DE965C3D-BF0B-44A8-B6B8-3BC080ECB196Q36745280-D4D9AF68-6DD4-4BD4-8ADD-D8C5835D9C8CQ36790858-FEE4A731-299B-425C-8DB9-400AD6851E57Q36794427-862B9E5F-C9C5-4D11-ADB8-BA6B42B146B1Q36828932-96C5B60B-3EA0-49B2-A8A5-073D10FC6BA5Q36868320-A118B373-1D91-42E8-BB42-87E62CDE5806Q36930349-2CB7AD41-711B-4383-8C59-D05A9AA39FC1Q37577162-9D9B99EB-9C8A-410D-95E2-3BD4DD7BB6CFQ37653125-BAC37823-1D4D-4094-8C83-7255523D69ABQ37660938-1180F23D-DD83-4A78-B1E7-36CD29CA33C2Q37670247-C900440B-98BB-4A0A-8D84-59B044F070B3Q38020015-52568D5A-A59E-411F-AD66-A05B708442B3Q38129446-A66CA8D5-3572-40AF-8390-59920C2D37B9Q38130502-20C223C9-BFAC-4984-9F09-9DC3E6DF8CC8Q38602464-877E3425-4E58-49D6-94C2-48D7DFE5CF3DQ38603504-47DE0AC9-8581-4100-B9B4-C0380ACB1148Q38641190-7BD59779-BFCD-4379-8F08-33011209A28FQ38744831-33DB5232-6449-4660-8BC0-3BF31BB12167Q38762377-3A338547-D396-4B6B-B8C7-D221E6FAC52B
P2860
Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Effects of rosiglitazone, glyb ...... insulin sensitivity in ADOPT.
@ast
Effects of rosiglitazone, glyb ...... insulin sensitivity in ADOPT.
@en
type
label
Effects of rosiglitazone, glyb ...... insulin sensitivity in ADOPT.
@ast
Effects of rosiglitazone, glyb ...... insulin sensitivity in ADOPT.
@en
prefLabel
Effects of rosiglitazone, glyb ...... insulin sensitivity in ADOPT.
@ast
Effects of rosiglitazone, glyb ...... insulin sensitivity in ADOPT.
@en
P2093
P2860
P50
P356
P1433
P1476
Effects of rosiglitazone, glyb ...... insulin sensitivity in ADOPT.
@en
P2093
ADOPT Study Group
Barbara G Kravitz
Giancarlo Viberti
Gitanjali Paul
R Paul Aftring
Rury R Holman
Steven M Haffner
William H Herman
P2860
P304
P356
10.2337/DB10-1392
P407
P577
2011-03-17T00:00:00Z